Makula M F, Coquet B, Plan R, Imbert C, Peyron L, Moulin J C, Liautaud J
Dev Biol Stand. 1987;67:257-65.
Having noted that the only physico-chemical and biological test recommended cannot ensure good tolerance of i.v. IgG in man, we studied a physiological test consisting of evaluating blood pressure during infusion in conscious dogs (10 mg/kg/min) or after i.v. injection in rats (250 mg/kg in 12 sec.). The data were obtained on more than 100 dogs and 500 rats. For preparations known to be well tolerated in man or inducing a few clinical intolerances, the correlation with hypotension in rats and dogs seems good. Therefore, we think this test has its place in the battery of i.v. IgG qualification tests carried out before passage to man. Institut Mérieux has developed a new intact i.v. IgG equilibrated in sub-classes, without PKA, low in IgA and not hypotensive in these two species.
鉴于已注意到所推荐的唯一物理化学和生物学测试不能确保人静脉注射免疫球蛋白(i.v. IgG)有良好耐受性,我们开展了一项生理学测试,该测试包括评估清醒犬类在输注期间(10毫克/千克/分钟)或大鼠静脉注射后(12秒内注射250毫克/千克)的血压。数据来自100多只犬和500多只大鼠。对于已知在人体中耐受性良好或仅引起少数临床不耐受情况的制剂,其与大鼠和犬类低血压的相关性似乎良好。因此,我们认为该测试在进入人体前进行的一系列静脉注射免疫球蛋白鉴定测试中具有一席之地。梅里埃研究所已研发出一种新的完整静脉注射免疫球蛋白,其亚类平衡,不含蛋白激酶A(PKA),IgA含量低,并且在这两个物种中不会引起低血压。